Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

por Rubinstein, Maria M., Doria, Eric Rios, Konner, Jason, Lichtman, Stuart, Zhou, Qin, Iasonos, Alexia, Sarasohn, Debra, Troso-Sandoval, Tiffany, Friedman, Claire, O'Cearbhaill, Roisin, Cadoo, Karen, Kyi, Chrisann, Cohen, Seth, Soldan, Krysten, Billinson, Eric, Caird, Imogen, Jang, Dasom, Eid, Khalil, Shah, Pooja, Guillen, Joyce, Aghajanian, Carol, Zamarin, Dmitriy, Makker, Vicky
Publicado 2023